TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”) by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with DARVIAS® for marketing rights in Japan.
Solasia Pharma K.K. (hereinafter “the Company”) hereby announces that its Board of Directors’ meeting today, has resolved to reduce the Company’s legal capital surplus, submit a proposal to reduce the amount of its capital stock to the 14th General Meeting of Shareholders of the Company which will be held on March 24, 2022 (hereinafter “the General Meeting”), and subject to such a reduction becoming effective, make an appropriation of surplus as follows. In addition, the Company has resolved to submit partial amendment to the Articles of Incorporation and a proposal of the election of the Directors to the General Meeting as follows.
Tokyo, Japan, February 14, 2022 – Solasia Pharma K.K. (TSE: 4597, Headquarter: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced fund raising via issuance of unsecured straight bonds (“Bond(s)”) and warrants (“Warrant(s)”) to Macquarie Bank Limited. Solasia looks to raise JPY 500mn via issuance of the Bonds, plus JPY 3,422mn via issuance of the Warrants (JPY 500mn of the exercise amount is planned to be utilized for redemption of the Bonds, hence actual total financing amount will be JPY 3,422mn). The funds will be used for SP-02 adaptation expansion, development in China and other development, and in-licensing of new development products.
Consolidated Financial Results for the Fiscal Year Ended December 31, 2021
Solasia Pharma K.K. (hereinafter “the Company”) today announced its Consolidated Financial Results for the Fiscal Year Ending December 31, 2021. The Company hereby supplements this information by providing notice of the status of its major pipeline products.
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”).
Solasia Pharma, a specialty pharmaceutical company based in Asia, announced the positive results from the pivotal phase 2 study with SP-02 (a new anti-cancer drug, international generic name: darinaparsin) for relapsed or refractory peripheral T-cell lymphoma (hereinafter PTCL) in Asia.